Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy
- 30 April 2004
- Vol. 34 (4) , 599-604
- https://doi.org/10.1016/j.bone.2003.12.022
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Treatment of postmenopausal osteoporosisThe Lancet, 2002
- Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive AgentsJournal of Clinical Endocrinology & Metabolism, 2002
- Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugsThe American Journal of Medicine, 2002
- Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene TherapyJournal of Bone and Mineral Research, 2002
- A method to assess the proportion of treatment effect explained by a surrogate endpointStatistics in Medicine, 2001
- Fluoride for the Treatment of Postmenopausal Osteoporotic Fractures: A Meta-AnalysisOsteoporosis International, 2000
- Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone DensityJournal of Clinical Endocrinology & Metabolism, 2000
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosisArthritis & Rheumatism, 1999
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996